Christopher Benbow
Psychiatry · la Jolla, CANPI 1205924503
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $273 and has fallen 92.8% since, to $20 in 2023.
Across 19 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$49
- Actelion Pharmaceuticals US, Inc.$44
- Otsuka America Pharmaceutical, Inc.$42
- Alkermes, Inc.$39
- Teva Pharmaceuticals USA, Inc.$36
- AbbVie$32
- plus $135 from 7 others
Across 746 payments — averaging $5823.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$970K
- Sunovion Pharmaceuticals Inc.$963K
- Teva Pharmaceuticals USA, Inc.$908K
- AbbVie$796K
- E.r. Squibb & Sons, L.L.C.$176K
- Hoffmann-la Roche Limited$173K
- plus $358K from 11 others
What the payments were for
- Food & beverage$34492%
- Education$328%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 3 | $49 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Alkermes, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| AbbVie | 1 | $32 |
| Amgen | 1 | $29 |
| IBSA Pharma Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Shire North American Group Inc | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
How this compares
$376 in reported general payments places this provider in the 60th percentile of 4,954 psychiatry providers in California.
Other psychiatry in la Jolla
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.